Imiquimod (IMQ), a synthetic toll-like receptor 7 (TLR-7) agonist is an FDA-approved immunotherapy drug which used in actinic keratosis, basal cell carcinoma, and Bowen’s disease treatment [9]. The gene discussed is TLR7; the disease is actinic keratosis.